Viridian Therapeutics, Inc./DE Amortization of Debt Issuance Costs and Discounts
Viridian Therapeutics, Inc./DE (VRDN) reported Amortization of Debt Issuance Costs and Discounts of $206.00 thousand for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2025-08-06
- Viridian Therapeutics, Inc./DE amortization of debt issuance costs and discounts for the quarter ending 2025-06-30 was $103.00K, a 16.26% decline year-over-year.
- Viridian Therapeutics, Inc./DE amortization of debt issuance costs and discounts for the quarter ending 2025-03-31 was $103.00K, a 16.26% decline year-over-year.
- Viridian Therapeutics, Inc./DE amortization of debt issuance costs and discounts for the quarter ending 2024-12-31 was $59.00K, a 52.03% decline year-over-year.
- Viridian Therapeutics, Inc./DE amortization of debt issuance costs and discounts for the quarter ending 2024-09-30 was $72.00K, a 17.24% decline year-over-year.
- Viridian Therapeutics, Inc./DE amortization of debt issuance costs and discounts for fiscal 2024 was $377.00K, a 18.93% increase from fiscal 2023.
- Viridian Therapeutics, Inc./DE amortization of debt issuance costs and discounts for fiscal 2023 was $317.00K, a 39.04% increase from fiscal 2022.
- Viridian Therapeutics, Inc./DE amortization of debt issuance costs and discounts for fiscal 2022 was $228.00K, a 162.07% increase from fiscal 2021.
- Viridian Therapeutics, Inc./DE amortization of debt issuance costs and discounts for fiscal 2021 was $87.00K.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2025-06-30 | $103.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $206.00K 10-Q · filed 2025-08-06 | $265.00K derived: sum of 3 quarters · filed 2025-08-06 | $337.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | $103.00K 10-Q · filed 2025-05-06 | $162.00K derived: sum of 2 quarters · filed 2025-05-06 | $234.00K derived: sum of 3 quarters · filed 2025-05-06 | $357.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-12-31 | $59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $131.00K derived: sum of 2 quarters · filed 2025-03-03 | $254.00K derived: sum of 3 quarters · filed 2025-08-06 | $377.00K 10-K · filed 2025-03-03 |
| 2024-09-30 | $72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $195.00K derived: sum of 2 quarters · filed 2025-08-06 | $318.00K 10-Q · filed 2024-11-12 | $441.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-06-30 | $123.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $246.00K 10-Q · filed 2025-08-06 | $369.00K derived: sum of 3 quarters · filed 2025-08-06 | $456.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $123.00K 10-Q · filed 2025-05-06 | $246.00K derived: sum of 2 quarters · filed 2025-05-06 | $333.00K derived: sum of 3 quarters · filed 2025-05-06 | $387.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $210.00K derived: sum of 2 quarters · filed 2025-03-03 | $264.00K derived: sum of 3 quarters · filed 2025-03-03 | $317.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | $87.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $141.00K derived: sum of 2 quarters · filed 2024-11-12 | $194.00K 10-Q · filed 2024-11-12 | $322.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $54.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $107.00K 10-Q · filed 2024-08-08 | $235.00K derived: sum of 3 quarters · filed 2025-03-03 | $284.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $53.00K 10-Q · filed 2024-05-08 | $181.00K derived: sum of 2 quarters · filed 2025-03-03 | $230.00K derived: sum of 3 quarters · filed 2025-03-03 | $281.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $177.00K derived: sum of 2 quarters · filed 2025-03-03 | $228.00K derived: sum of 3 quarters · filed 2025-03-03 | $228.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $100.00K derived: sum of 2 quarters · filed 2023-11-13 | $100.00K 10-Q · filed 2023-11-13 | $187.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $51.00K 10-Q · filed 2023-08-08 | $138.00K derived: sum of 3 quarters · filed 2024-02-27 | $138.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | $87.00K derived: sum of 2 quarters · filed 2024-02-27 | $87.00K derived: sum of 3 quarters · filed 2024-02-27 | |
| 2021-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $87.00K derived: sum of 2 quarters · filed 2024-02-27 | $87.00K 10-K · filed 2024-02-27 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |